Medical Condition News

RSS

Great American Asthma Challenge movement to change asthma care in the U.S.

Every day 10 people die from asthma. Most healthcare providers agree that these deaths are preventable. Patient education, access to care and a healthy lifestyle are proven methods that lead to less severe asthma symptoms, fewer hospitalizations and emergency department visits, fewer missed days of school and work - and fewer deaths.

29 Apr 2010

Healthy food programs in grocery stores may help reduce diet-related illnesses

Bringing healthy food programs to corner grocery stores in the inner city might be a step toward improving residents' diet and reducing diet-related illnesses, a new study suggests.

29 Apr 2010

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

29 Apr 2010

Renowned cardiologists to discuss latest research on Hypertrophic Cardiomyopathy at HCMA symposium

Hypertrophic Cardiomyopathy (HCM), the genetic disease in which the muscle of the heart thickens in the absence of an apparent cause, is the leading cause of sudden death in children and young adults. HCM accounts for 40 percent of all deaths on athletic playing fields across the U.S.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Tumor cell factories may be difficult to defeat: Researchers

Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells.

29 Apr 2010

Vascular surgeon successfully bypasses torn aorta

Rhonda Mullen was 38 years old and in perfect health when she suddenly felt a searing pain between her shoulder blades. A few hours later, Mullen was being wheeled into an operating room at Loyola University Hospital for emergency surgery to repair an unusual tear in her aorta, the body's main blood vessel.

29 Apr 2010

Investigators study Pioglitazone and Vitamin E for treatment of NASH

A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.

29 Apr 2010

Many Americans aren't taking necessary steps to protect against diabetes: Study

Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention. However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren't taking the necessary steps to protect their health, according to a recent study by the International Diabetes Center and Abbott.

28 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Subtle changes in PTEN protein levels increase chances of developing cancer

A US study has found that even subtle changes in the levels of PTEN, a protein that blocks cancer development, may significantly increase a person's chances of developing cancer.

28 Apr 2010

Building motivation may be effective means of promoting adherence, weight loss: Study

Energy in, energy out, it's the basic equation to weight loss, or is it? With more than two thirds of Americans classified as overweight or obese1, a study in the May/June 2010 issue of the Journal of Nutrition Education and Behavior examines how motivation might be a large contributor to sticking with weight loss programs.

28 Apr 2010

Scientists discover human DNA that act as a traitor to body's defences

Cancer Research UK-funded scientists have discovered that stretches of human DNA act as a traitor to the body's defences by helping viruses infect people and trigger cancer-causing diseases, according to a study published in Nature Cell Biology today.

28 Apr 2010

New study links psychopathy to frontal lobe dysfunction

Psychopaths are known to be characterized by callousness, diminished capacity for remorse, and lack of empathy. However, the exact cause of these personality traits is an area of scientific debate. The results of a new study, reported in the May 2010 issue of Elsevier's Cortex, show striking similarities between the mental impairments observed in psychopaths and those seen in patients with frontal lobe damage.

28 Apr 2010

Awareness of cancer health disparities, burden of current economic crisis to be explored at 3-day forum

Awareness of cancer health disparities, the burden of the current economic crisis on these inequities, and interventions and policy initiatives to improve health disparities will be explored during a three-day forum hosted by the University of Michigan Comprehensive Cancer Center and the Horace H. Rackham School of Graduate Studies.

28 Apr 2010

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month.

28 Apr 2010

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions. There are currently no treatment options for people with this debilitating disease. The research is published in the April 27 issue of Proceedings of the National Academy of Sciences.

28 Apr 2010

Diamyd Medical to focus on completion of Diamyd Phase III studies and preparation for market launch

“Besides our ongoing partnership discussions, we will primarily focus on completing the Phase III studies and prepare for market launch of Diamyd®.”

28 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Medical Condition News

Great American Asthma Challenge movement to change asthma care in the U.S.

Healthy food programs in grocery stores may help reduce diet-related illnesses

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Renowned cardiologists to discuss latest research on Hypertrophic Cardiomyopathy at HCMA symposium

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Tumor cell factories may be difficult to defeat: Researchers

Vascular surgeon successfully bypasses torn aorta

Investigators study Pioglitazone and Vitamin E for treatment of NASH

Many Americans aren't taking necessary steps to protect against diabetes: Study

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Subtle changes in PTEN protein levels increase chances of developing cancer

Building motivation may be effective means of promoting adherence, weight loss: Study

Scientists discover human DNA that act as a traitor to body's defences

New study links psychopathy to frontal lobe dysfunction

Awareness of cancer health disparities, burden of current economic crisis to be explored at 3-day forum

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Diamyd Medical to focus on completion of Diamyd Phase III studies and preparation for market launch

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News